DGAP-News: ABIVAX
/ Key word(s): Personnel
Abivax appoints Dr Sophie Biguenet, M.D., as Chief Medical Officer
01.03.2021 / 18:00
Abivax
Chief Medical Officer
Dr Sophie Biguenet joins Abivax on March 1
As CMO, Sophie Biguenet will drive Abivax's main clinical program of ABX464 for the treatment of inflammatory bowel diseases (IBD) into phase 3 testing in 2021
PARIS, March 1, 2021 - 06:00 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company modulating the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announces the appointment of Dr Sophie Biguenet as Chief Medical Officer, effective on March 1, 2021, based in Paris. Dr Biguenet brings 25 years of experience in academia and in the biopharmaceutical industry with an extensive track record in international clinical development, leading to the successful registration of several new drug products across various treatment areas, including immunology, virology and liver diseases. In her new role, she follows Dr Jean-Marc Steens, M.D., who plans to retire within the next several months after six years as Abivax's CMO. Dr Steens has been actively involved in the successful clinical transition of lead compound ABX464 into late-stage clinical testing in chronic inflammatory diseases.